What drove LNTH's earnings growth in 2024?

Lantheus Holdings' earnings growth in 2024 was primarily driven by the significant increase in sales of its flagship product, PYLARIFY. According to the company's earnings report, PYLARIFY generated sales of $266 million in Q4 2024, marking a 15.7% year-over-year growth. This growth was driven by volume increases at existing accounts and a slight increase in net price. The success of PYLARIFY was a key factor in Lantheus Holdings' overall revenue growth and its ability to surpass earnings estimates. In addition to PYLARIFY's growth, the company's strategic acquisitions, such as Life Molecular Imaging and Evergreen Theragnostics, are expected to support future growth and expand capabilities in areas like Alzheimer's disease radiodiagnostics and oncology radiotherapeutics. Furthermore, Lantheus Holdings' focus on business development and R&D investments, as evidenced by their announcements of new product candidates and expanded portfolio, indicates a commitment to innovation that contributes to its growth potential. In summary, PYLARIFY's sales growth, strategic acquisitions, and commitment to R&D are the key drivers behind Lantheus Holdings' earnings growth in 2024.